tiprankstipranks
Trending News
More News >
Well Health Technologies (TSE:WELL)
:WELL
Advertisement

WELL Health Technologies Corp (WELL) AI Stock Analysis

Compare
2,197 Followers

Top Page

TSE:WELL

WELL Health Technologies Corp

(TSX:WELL)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 4o)
Rating:46Neutral
Price Target:
C$4.50
▼(-11.24% Downside)
WELL Health Technologies Corp's overall stock score is primarily influenced by its strong revenue growth, which is offset by challenges in profitability and cash flow management. Technical indicators suggest a neutral to slightly negative outlook, while valuation is impacted by a negative P/E ratio and lack of dividend yield.
Positive Factors
Revenue Growth
The company's strong revenue growth indicates a robust demand for its healthcare services and technology solutions, suggesting a solid market position and potential for continued expansion.
Diversified Revenue Streams
A diversified revenue model reduces dependency on a single income source, enhancing financial stability and resilience against market fluctuations.
Moderate Debt Levels
A moderate debt-to-equity ratio suggests a balanced approach to leveraging, providing financial flexibility and reducing risk associated with high leverage.
Negative Factors
Profitability Challenges
Negative profitability metrics indicate challenges in cost management and pricing strategy, which could hinder long-term financial health and shareholder returns.
Cash Flow Issues
Negative free cash flow suggests difficulties in generating sufficient cash from operations, potentially impacting the company's ability to fund growth and meet financial obligations.
Decreasing Gross Profit Margin
A declining gross profit margin may indicate rising costs or pricing pressures, which could erode profitability and competitiveness over the long term.

WELL Health Technologies Corp (WELL) vs. iShares MSCI Canada ETF (EWC)

WELL Health Technologies Corp Business Overview & Revenue Model

Company DescriptionWELL Health Technologies Corp. operates as a practitioner focused digital health company in Canada, the United States, and internationally. It offers end-to-end omni-channel patient services, including primary care; physiotherapy, occupational therapy, chiropractic, dietary, mental health counselling, and sleep related services; specialized care, including gastroenterologists; diagnostic services related to cardiology, women's health, and bone/muscle health and cancer diagnostics; and telehealth services. The company also operates OSCAR Pro, an electronic medical records platform; telehealth platforms, including Tia Health, VirtualClinic+, VirtuelMed, Adracare, and Circle Medical; Apps.health, a digital health app marketplace; Insig, which offers virtual care and digital patient engagement services; billing and revenue cycle management solutions for billing and back-office services comprising billing-as-a-service outsourcing services to doctors; and cybersecurity protection and patient data privacy solutions. As of December 31, 2021, the company operated 30 primary care and executive care clinics; and provides primary care, specialty care, and accredited diagnostic health services through 49 locations across Ontario. The company was formerly known as Wellness Lifestyles Inc. and changed its name to WELL Health Technologies Corp. in July 2018. WELL Health Technologies Corp. was incorporated in 2010 and is headquartered in Vancouver, Canada.
How the Company Makes MoneyWELL Health Technologies Corp generates revenue through multiple streams. The primary revenue model includes fees from healthcare clinics, which offer various medical services to patients. Additionally, the company earns income through its digital health solutions, including subscription and licensing fees for its electronic medical records (EMR) software, which is used by healthcare providers to manage patient information. WELL also derives revenue from telehealth services, where patients are charged for virtual consultations. The company has established key partnerships with healthcare providers and technology firms to expand its service offerings and reach. The combination of these services and strategic partnerships allows WELL to maintain a diverse and stable revenue base.

WELL Health Technologies Corp Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q3-2024)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call was positive overall, with record-setting performances in revenue, EBITDA, and patient visits. Despite challenges like unrealized losses on investments and weather-related impacts, WELL Health's strategic initiatives and strong M&A pipeline position the company for continued growth.
Q3-2024 Updates
Positive Updates
Record Quarterly Performance
The third quarter of 2024 was one of the best in WELL Health's history, with record performances in revenue, adjusted EBITDA, free cash flow, patient visits, and organic growth.
Surpassed $1 Billion Revenue Run Rate
WELL Health surpassed $1 billion in annualized revenue run rate, one quarter ahead of schedule, representing a 30-fold increase over five years.
Strong Revenue and EBITDA Growth
Robust revenue growth of 35% in Canadian patient services and 23% overall organic growth, with adjusted EBITDA of $32.7 million reflecting 16% year-over-year growth.
Record Free Cash Flow
Adjusted free cash flow to shareholders increased by 69% year-over-year and 85% quarter-over-quarter, reaching $0.065 per share.
Significant Debt Reduction
Paid down significant debt, improving leverage ratio to approximately 2.5 from 2.67 in the previous quarter.
Record Patient Visits
Achieved a record 1.5 million patient visits in Q3 2024, a 41% year-over-year increase, with 31% organic growth.
Increased Revenue Guidance
Raised 2024 annual revenue guidance to between $985 million and $995 million.
Strong M&A Pipeline
17 LOIs and deals pending closure, representing over $100 million in annual revenue.
Circle Medical and Wisp Growth
Circle Medical's revenue increased by 61% year-over-year with adjusted EBITDA of $2.6 million, and Wisp achieved record revenue and adjusted EBITDA growth.
Negative Updates
Unrealized Loss on HEALWELL AI Investment
Reported an IFRS net loss of $75.8 million in Q3 2024, primarily due to unrealized losses on WELL's investment in HEALWELL AI.
Impact of Hurricanes
Hurricanes Helen and Milton impacted CRH's revenue, resulting in a minimal revenue loss of approximately CAD 500,000 and an additional $1 to $1.5 million in Q4.
Delayed Billing and Cash Collections
CRH experienced delays in billing and cash collections due to a cybersecurity incident at its billing partner, Change Healthcare.
Company Guidance
In the Q3 2024 earnings call, WELL Health Technologies Corp. provided guidance that highlights several key performance metrics. The company reported record quarterly revenue of $251.7 million, a 23% year-over-year increase driven by 23% organic growth. Adjusted EBITDA reached $32.7 million, reflecting a 16% growth, while adjusted free cash flow to shareholders rose by 69% compared to Q3 2023. WELL surpassed a $1 billion annualized revenue run rate, achieving this milestone one quarter ahead of schedule. The company also increased its annual revenue guidance to between $985 million and $995 million, attributing the rise to recent clinic acquisitions and robust organic growth. Despite revenue growth, annual adjusted EBITDA guidance remains in the upper half of $125 million to $130 million. Additionally, WELL's leverage ratio improved to approximately 2.5, and the company expects its adjusted free cash flow available to shareholders to be around $55 million for 2024. The strategy includes continued strong execution across all business units, with a focus on enhanced profitability, capital efficiency, and organic growth.

WELL Health Technologies Corp Financial Statement Overview

Summary
WELL Health Technologies Corp shows strong revenue growth but struggles with profitability and cash flow management. The balance sheet is stable, but negative profitability and cash flow conversion issues need addressing.
Income Statement
45
Neutral
WELL Health Technologies Corp has shown a positive revenue growth rate of 11.56% in the TTM, indicating a strong upward trajectory in sales. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased over time, reflecting potential cost management issues.
Balance Sheet
55
Neutral
The company's debt-to-equity ratio is moderate at 0.57, suggesting a balanced approach to leveraging. However, the negative return on equity in the TTM indicates challenges in generating returns for shareholders. The equity ratio is stable, showing a solid capital structure.
Cash Flow
40
Negative
The cash flow statement reveals a significant improvement in free cash flow growth rate, but the free cash flow remains negative. The operating cash flow to net income ratio is low, indicating potential issues in converting income into cash. The free cash flow to net income ratio is also negative, highlighting cash flow challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.10B919.69M776.05M569.14M302.32M50.24M
Gross Profit429.62M363.01M372.27M303.29M153.69M21.22M
EBITDA-19.20M122.52M101.88M95.99M21.27M-495.00K
Net Income-128.62M32.61M82.00K19.07M-30.69M-2.62M
Balance Sheet
Total Assets2.02B1.81B1.41B1.32B1.26B262.73M
Cash, Cash Equivalents and Short-Term Investments98.89M131.67M43.42M48.91M61.92M86.89M
Total Debt569.76M425.09M426.28M358.42M401.94M23.57M
Total Liabilities1.03B877.55M563.16M503.78M554.37M43.75M
Stockholders Equity826.20M867.61M767.67M732.34M618.24M217.37M
Cash Flow
Free Cash Flow-17.33M-6.70M37.20M70.14M19.59M-6.52M
Operating Cash Flow3.93M9.52M66.44M76.55M22.27M-5.38M
Investing Cash Flow-86.18M-60.23M-106.42M-37.93M-499.78M-44.21M
Financing Cash Flow133.09M133.50M10.63M-52.85M452.53M120.84M

WELL Health Technologies Corp Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.07
Price Trends
50DMA
4.78
Positive
100DMA
4.44
Positive
200DMA
5.07
Positive
Market Momentum
MACD
0.08
Negative
RSI
62.55
Neutral
STOCH
81.42
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:WELL, the sentiment is Positive. The current price of 5.07 is above the 20-day moving average (MA) of 4.77, above the 50-day MA of 4.78, and above the 200-day MA of 5.07, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 62.55 is Neutral, neither overbought nor oversold. The STOCH value of 81.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:WELL.

WELL Health Technologies Corp Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
30.56M184.217.55%11.89%5.56%
61
Neutral
1.68B-35.87-2.55%0.59%9.94%35.48%
59
Neutral
269.31M2.09105.57%2.47%-35.35%948.72%
53
Neutral
206.22M-110.81-2.09%0.61%-0.16%75.25%
46
Neutral
C$1.29B30.45-14.61%20.36%-186.10%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:WELL
WELL Health Technologies Corp
5.07
0.67
15.23%
TSE:CRRX
CareRx
3.28
1.42
76.34%
TSE:NLH
Nova Leap Health
0.35
0.10
40.00%
MFCSF
Medical Facilities
10.12
0.19
1.91%
TSE:DNTL
dentalcorp Holdings
8.44
0.20
2.43%

WELL Health Technologies Corp Corporate Events

Business Operations and StrategyFinancial Disclosures
WELL Health Technologies Achieves Record Q2-2025 Results and Milestone Patient Visits
Positive
Aug 14, 2025

WELL Health Technologies Corp reported record financial results for Q2-2025, achieving a 57% increase in quarterly revenues to $356.7 million, driven by organic growth and acquisitions. The company also marked its first-ever quarter with over 1 million patient visits in Canada, reflecting a 38% year-over-year growth. WELL’s strategic investments in Canadian clinics and technology have led to improved provider productivity and significant milestones in financial metrics, including Adjusted EBITDA and net income. The inclusion of HEALWELL AI contributed $40.5 million to revenue, and the company is considering strategic alternatives for its U.S. assets to focus on core Canadian operations.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

Financial Disclosures
WELL Health to Release Q2 2025 Financial Results
Neutral
Jul 28, 2025

WELL Health Technologies Corp. announced it will release its second quarter 2025 financial results on August 14, 2025. The company will hold a conference call and webcast to discuss the results, led by CEO Hamed Shahbazi and CFO Eva Fong. This announcement reflects WELL’s ongoing commitment to transparency and engagement with stakeholders, as it continues to expand its influence in the digital healthcare industry.

The most recent analyst rating on (TSE:WELL) stock is a Buy with a C$6.00 price target. To see the full list of analyst forecasts on WELL Health Technologies Corp stock, see the TSE:WELL Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 19, 2025